While most of the attention in the biotech space is currently focused on companies working on potential vaccines for the novel coronavirus and treatments for the disease it causes, COVID-19, the author of today’s article reminds us that “the rest of the biopharma industry didn’t vanish because of the coronavirus pandemic. While clinical trials will likely be delayed across the industry as a result of the current situation, all of the most promising long-term investing opportunities that existed in late February still exist today.” For two non-COVID-19 biotech stocks to consider buying right now, CLICK HERE.